Overview

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with topotecan works in treating patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cavity cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Gemcitabine
Topotecan
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of ovarian, fallopian tube, or primary peritoneal cavity cancer

- Recurrent or persistent platinum-refractory disease, as defined by 1 of the following:

- Progressive disease while on a platinum compound

- Persistent clinically measurable disease with best response as stable disease at
the completion of ≥ 6 courses of therapy

- Recurrent disease within 6 months after completion of therapy

- Measurable or evaluable disease

- Evaluable disease, defined as CA 125 ≥ 100 U/mL (confirmed by 2 blood tests)

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques, including palpation, plain x-ray, CT scan, or MRI, OR ≥
10 mm by spiral CT scan

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- GOG 0-3

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

Hepatic

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- SGOT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

Renal

- Creatinine ≤ 1.5 times ULN

- Creatinine clearance > 50 mL/min

Other

- No clinically significant infection

- No other severe medical condition that would preclude study treatment

- No other malignancy within the past 5 years except nonmelanoma skin cancer or
carcinoma in situ of the cervix or breast

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- See Disease Characteristics

- Prior gemcitabine or topotecan allowed provided disease is not refractory to either
drug

- At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

- Not specified

Radiotherapy

- At least 3 weeks since prior radiotherapy and recovered

Surgery

- Recovered from recent prior surgery